EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes

Xuefen Yin iD, Brian Cicali iD, Leyanis Rodriguez-Vera iD, Viera Lukacova, Rodrigo Cristofoletti, Stephan Schmidt iD

Pharmaceutics · 30.05.2024 · 16 (6) · 737

DOI: 10.3390/pharmaceutics16060737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.05.2024. Verfasst von Xuefen Yin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Simulations-Plus.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Carbamazepine (CBZ) is commonly prescribed for epilepsy and frequently used in polypharmacy. However, concerns arise regarding its ability to induce the metabolism of other drugs, including itself, potentially leading to the undertreatment of co-administered drugs. Additionally, CBZ exhibits nonlinear pharmacokinetics (PK), but the root causes have not been fully studied. This study aims to investigate the mechanisms behind CBZ’s nonlinear PK and its induction potential on CYP3A4 and CYP2C9 enzymes. To achieve this, we developed and validated a physiologically based pharmacokinetic (PBPK) parent–metabolite model of CBZ and its active metabolite Carbamazepine-10,11-epoxide in GastroPlus®. The model was utilized for Drug–Drug Interaction (DDI) prediction with CYP3A4 and CYP2C9 victim drugs and to further explore the underlying mechanisms behind CBZ’s nonlinear PK. The model accurately recapitulated CBZ plasma PK. Good DDI performance was demonstrated by the prediction of CBZ DDIs with quinidine, dolutegravir, phenytoin, and tolbutamide; however, with midazolam, the predicted/observed DDI AUClast ratio was 0.49 (slightly outside of the two-fold range). CBZ’s nonlinear PK can be attributed to its nonlinear metabolism caused by autoinduction, as well as nonlinear absorption due to poor solubility. In further applications, the model can help understand DDI potential when CBZ serves as a CYP3A4 and CYP2C9 inducer.

Schlagwörter

Stichwörter der Autor:innen

Carbamazepine-10,11-epoxideDrug–Drug Interaction (DDI)carbamazepinecytochrome P450 2C9 (CYP2C9)cytochrome P450 3A4 (CYP3A4)inductionphysiologically based pharmacokinetic (PBPK) modeling

Autor:innen und Institutionen

  • Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, Orlando, FL 32827, USA.
  • Simulations Plus, Lancaster, CA 93534, USA.

ORCID-Profile: Xuefen Yin, Brian Cicali, Leyanis Rodriguez-Vera, Stephan Schmidt

Förderung

  • Simulations-Plus

Zitieren

APA

Yin, X., Cicali, B., Rodriguez-Vera, L., Lukacova, V., Cristofoletti, R., & Schmidt, S. (2024). Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes. Pharmaceutics, 16(6), 737. https://doi.org/10.3390/pharmaceutics16060737

Vancouver

Yin X, Cicali B, Rodriguez-Vera L, Lukacova V, Cristofoletti R, Schmidt S. Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes. Pharmaceutics. 2024;16(6):737. doi:10.3390/pharmaceutics16060737

BibTeX
@article{Yin2024,
  author = {Yin, Xuefen and Cicali, Brian and Rodriguez-Vera, Leyanis and Lukacova, Viera and Cristofoletti, Rodrigo and Schmidt, Stephan},
  title = {Applying Physiologically Based Pharmacokinetic Modeling to Interpret Carbamazepine’s Nonlinear Pharmacokinetics and Its Induction Potential on Cytochrome P450 3A4 and Cytochrome P450 2C9 Enzymes},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {737},
  doi = {10.3390/pharmaceutics16060737}
}
Kostenlos starten →